Novo Nordisk AS - Company Profile
Powered by
All the data and insights you need on Novo Nordisk AS in one report.
$295
- Save hours of research time and resources with
our up-to-date Novo Nordisk AS Strategy Report
- Understand Novo Nordisk AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View more- Top 10 Pharmaceutical Companies in Europe in 2022 by Market Capitalization
- Top 10 Pharmaceutical Companies in the World in 2022 by Market Capitalization
- Top 10 Pharma Companies in Europe in 2021 by R&D Expenditure
- Top 10 Big Biopharma Companies (Large Pharma & Large Biotech) in Europe in 2021 by Revenues
View up-to-date information on Novo Nordisk AS patents, including inventor and filing insights.
Patent Trends
Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
---|---|---|---|---|
CN115052898A | Application | 双特异性因子VIII模拟抗体 | A61P7/04; C07K16/36; C07K2317/21; C07K2317/31; C07K2317/75 | September 13, 2022 |
US20220280611A1 | Application | SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID | A61K38/26; A61K9/1617; A61K9/1652; A61K9/2054; A61P3/04; A61P3/10 | September 08, 2022 |
US20220280612A1 | Application | GLP-1 RECEPTOR AGONISTS IN DEMENTIA | A61K38/26; A61K9/2013; A61P25/28 | September 08, 2022 |
CN108136043B | Grant | 蛋白质缀合物 | A61K38/27; A61K47/646; A61K47/65; A61K47/6811; A61K47/6889; A61P5/06; C07K14/61 | September 06, 2022 |
CN109069589B | Grant | 用于心血管病况的司美鲁肽 | A61K38/26; A61P3/10; A61P9/10 | September 06, 2022 |
Top Inventors by Filings (Count by publication)
Name | Count |
---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer